Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
The BEACON update, based on a data-cut date of January 31, 2025, features approximately one month of additional dosing and follow-up from the 49 participants covered in Jasper's preliminary data disclosure on January 8, 2025. Briquilimab continues to be well tolerated in the study and has continued to demonstrate a favorable safety profile, with no additional adverse events (AEs) potentially related to c-Kit blockade observed. The data collected in the study to-date support advancing briquilimab into a registrational program in CSU, beginning with a planned Phase 2b operationally adaptive study expected to commence in the second half of 2025. Final dose selection for the Phase 2b study will be further informed by additional clinical data from patients treated at doses of 180mg and higher, expected to be reported mid-year 2025.
'I am pleased to present updated data from the BEACON study at AAAAI, which continue to demonstrate that treatment with briquilimab leads to rapid and deep clinical responses in omalizumab-experienced patients with moderate to severe CSU,' said Thomas B. Casale, M.D., Professor of Medicine and Pediatrics, University of South Florida Morsani College of Medicine. 'The safety profile observed is also highly encouraging, with a low frequency of c-Kit related adverse events, which were transient, low-grade, and did not result in any dose delays or discontinuations. The favorable safety data reported in the study are supported by the predictable drug clearance observed, which may allow for restoration of signaling on c-Kit-expressing cells between doses. In addition, the early Tmax observed was consistent with rapid onset of clinical response. Taken together, I believe this data set underscores the potential of briquilimab to serve as a differentiated treatment option for patients with CSU.'
'We remain very excited by the efficacy and safety data generated in the BEACON study,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'We believe that these data demonstrate the potential of briquilimab to differentiate from other therapies, approved and in-development, with regard to onset of action, depth of response, and safety/tolerability. With a substantial number of additional patients being enrolled in the BEACON and SPOTLIGHT studies, as well as patients rolling over from those studies to the Open-Label Extension study, we look forward to reporting data from approximately 70 additional patients treated with briquilimab doses of 180mg or higher around mid-year 2025. These data will inform final dose selection for our planned Phase 2b operationally adaptive study expected to commence later this year.'
Details of the presentations are as follows:
Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)Publication Number: L24Session Title: Late Breaking Oral Abstract SessionSession Type: Oral Abstract SessionPresentation Date / Time: Saturday, March 1, 2025; 2:55 p.m. PST
Abstract Title: Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)Poster Number: L24Session Title: Late Breaking Poster Session ISession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab, an Anti-c-Kit Antibody, Induces Durable Depletion of Mast Cells (MCs) Across Multiple Tissues in Mice Expressing Chimeric Human/Mouse CD117 (c-Kit)Poster Number: 540Session Title: Novel Mechanisms of Mast Cells, Basophils and IgESession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell ApoptosisPoster Number: 541Session Title: Novel Mechanisms of Mast Cells, Basophils and IgESession Type: Poster SessionSession Date / Time: Saturday, March 1, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Prevents Epicutaneous Oxazolone-Induced Features of Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117Poster Number: 662Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, AngioedemaSession Type: Poster SessionSession Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST
Abstract Title: Briquilimab, an Anti-Human CD117 Antibody, Treats Low-Calcemic Vitamin D3 Analog MC903-Induced Dermatitis in Mouse Model Expressing Chimeric Human/Mouse CD117Poster Number: 690Session Title: Atopic Dermatitis, Contact Dermatitis, Urticaria, AngioedemaSession Type: Poster SessionSession Date / Time: Sunday, March 2, 2025; 9:45 - 10:45 a.m. PST
About Jasper
Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at www.jaspertx.com.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma, its potential to serve as a differentiated treatment option for patients with CSU, its potential to differentiate from other therapies, approved and in-development, with regard to onset of action, depth of response, and safety/tolerability and its potential allow for restoration of signaling on c-Kit-expressing cells between doses; Jasper's expectations regarding advancing briquilimab into a registrational program in CSU, including the potential commencement of a Phase 2b operationally adaptive study and the expected timing for commencing such trial; the expected timing for reporting additional clinical data from the Phase 1b/2a BEACON study for patients treated at doses of 180mg and higher; and Jasper's poster presentations and oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:
Alex Gray (investors)Jasper Therapeutics650-549-1454 agray@jaspertherapeutics.com
Joyce Allaire (investors)LifeSci Advisors617-435-6602jallaire@lifesciadvisors.com
Lauren Walker (media)Real Chemistry646-564-2156lbarbiero@realchemistry.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 minutes ago
- Business Wire
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--The law firm of Kahn Swick & Foti, LLC ('KSF') has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) ('Immunovant'). KSF is investigating whether Immunovant's officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws. If you hold shares of Immunovant, Inc. (NasdaqGS: IMVT), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-free at 1-833-938-0905, or by e-mailing KSF Managing Partner, Lewis Kahn, ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
Bloomberg
3 minutes ago
- Bloomberg
CK Hutchison Investors Eye Port Sale Update Ahead of Earnings
The next leg of CK Hutchison Holdings Ltd. 's stock rally will depend in large part on any update the conglomerate may provide on its politically sensitive global port asset sale. Shares of Hong Kong tycoon Li Ka-shing's firm have soared about 35% since an April low. The rally followed a roller-coaster ride after it first announced in March a deal to sell the assets to a consortium led by BlackRock Inc. The transaction, which includes a controlling stake in Panama ports, has since then stalled after Beijing viewed it as a threat to its interests.
Yahoo
6 minutes ago
- Yahoo
Orezone Gold Reports Second Quarter 2025 Results
All dollar amounts are in USD unless otherwise indicated and abbreviation 'M' means million. VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX/ASX: ORE, OTCQX: ORZCF) ('Orezone' or 'Company') is pleased to report its operational and financial results for the three and six months ended June 30, 2025. The Company will host a conference call and webcast today at 2:00pm PT / 5:00pm ET (August 14, 7:00am AEST) to discuss the results. Details to join the conference call and webcast are provided at the end of this release. Second Quarter 2025 Highlights Gold production of 27,548 ounces at an AISC of $1,830 per ounce sold Revenue of $94.5M from the sale of 28,265 ounces at an average realized price of $3,338 per ounce Adjusted EBITDA of $45.5M, Adjusted Earnings attributable to Orezone shareholders of $20.6M, and Adjusted Earnings per Share attributable to Orezone shareholders of $0.04 Liquidity of $103.9M at June 30, 2025 with cash of $72.6M and undrawn senior debt of $31.3M Stage 1 hard rock expansion reached 63% completion and remains on schedule for first gold in Q4-2025. Stage 1 is forecasted to increase overall gold production to 170,000-185,000 ounces in 20261. Click link here for August construction video Subsequent to quarter end: Completed A$75.0M initial public offering on the Australian Securities Exchange ('ASX') and commenced trading under the symbol 'ORE'. Proceeds will accelerate the stage 2 hard rock expansion Board approved construction decision for the stage 2 hard rock expansion. Stage 2 commissioning scheduled for Q4-2026, with overall gold production forecasted to increase to 220,000-250,000 ounces per annum2 Patrick Downey, President and CEO, commented 'Q2 marked another solid operating quarter at Bomboré, with all production metrics, including grade, recovery, and tonnes processed, inline with plan. This is a testament to the site operating team, who remain focused on operational excellence. During Q2, this included several stage 1 hard rock operational readiness initiatives, including 1) maintaining an elevated mining rate through the onset of the rainy season to advance a number of pits to the hard rock interface, and 2) processing a greater percentage of corresponding transitional material while achieving a mill throughput rate at 20% above nameplate. The higher realized AISC in Q2 was mainly attributable to external factors including higher royalties, lower grid power availability and unfavourable foreign exchange movements. The higher royalty costs were the result of a record realized gold price of $3,338/oz versus the budgeted $2,600/oz, along with a newly enacted royalty structure that added 1% to the royalty rates. The lower than expected grid power availability that led to more power generation onsite using higher cost diesel, was the result of a fire at a supply line substation, and higher than forecasted seasonal variability, which year over year has materially improved. A steady improvement in grid power has been seen in the past two months with utilization increasing from 50% in Q2, to 76% in July, and a return to >90% in August. The XOF strengthened against the USD by over 7% from Q1 to Q2 which negatively impacted reported costs as the majority of operating expenditures are in the local currency. These three external factors combined are estimated to have added $236 per ounce to the guided AISC per ounce sold in Q2. Through Q2, the Company made steady progress on its multiple growth initiatives. The construction of the stage 1 hard rock plant remains on schedule and on budget, with first gold on track for Q4-2025. This will mark an important milestone for the Company with overall gold production at Bomboré forecasted to increase to 170,000-185,000 ounces in 20263. On the stage 2 hard rock expansion, early progress was made advancing engineering, scheduling and initial procurement, with a Board approved construction decision made subsequent to quarter end. Executing on these growth initiatives over the next 16 months will significantly transform the Company by increasing overall production at Bomboré to 220,000-250,000 ounces per annum4. This production growth will be complemented by an ongoing focus on exploration, with the goal of increasing the current resource base to a targeted 7 to 10 million ounces longer term5. Exploration drilling through H1-2025 was successful on multiple fronts, further underscoring the significant exploration upside to the current stated 5.0 million ounce global resource base at Bomboré. Results included 1) extending the North Zone footwall mineralization up to 200m below the current reserve pits along 800m strike length, 2) extending mineralization of the P17S high-grade sub-zone a further 300m down plunge, and 3) identifying multiple broad near-surface strike extensions. Following several months of hard work, Orezone has commenced trading on the ASX under the ticker 'ORE'. The secondary listing on the ASX has broadened our investor base into the very active Australian mining market, enhancing the Company's capital markets profile and trading liquidity.' ________________________1 Refer to the Company's Prospectus dated July 11, 2025, a copy of which is available on the Company's website. The Company confirms it is not aware of any new information or data that materially affects the information included in the Prospectus and that all material assumptions and technical parameters underpinning the forecast gold production targets in the Prospectus continue to apply and have not materially changed.2 Refer to footnote 1.3 Refer to footnote 1.4 Refer to footnote 1.5 This statement of the Company's goal of increasing the current stated 5 million ounce global resource base to a targeted 7 to 10 million ounces longer term is an aspirational statement, and the Company does not yet have reasonable grounds to believe the statement can be achieved. Highlights for the Second Quarter and Significant Subsequent Events (All mine site figures on a 100% basis) Q2-2025 Q2-2024 H1-2025 H1-2024 Operating Performance Gold production oz 27,548 25,524 56,236 55,663 Gold sales oz 28,265 24,937 57,208 56,166 Average realized gold price $/oz 3,338 2,334 3,092 2,185 Cash costs per gold ounce sold1 $/oz 1,609 1,386 1,415 1,242 All-in sustaining costs1 ('AISC') per gold ounce sold $/oz 1,830 1,613 1,620 1,452 Financial Performance Revenue $000's 94,512 58,343 177,227 123,028 Earnings from mine operations $000's 39,951 23,167 78,514 50,049 Net earnings attributable to shareholders of Orezone $000's 15,906 8,939 31,885 20,636 Net earnings per common share attributable to shareholders of Orezone Basic $ 0.03 0.02 0.06 0.06 Diluted $ 0.03 0.02 0.06 0.05 EBITDA1 $000's 40,270 26,728 81,452 57,057 Adjusted EBITDA1 $000's 45,493 20,491 89,687 46,419 Adjusted earnings attributable to shareholders of Orezone1 $000's 20,607 3,326 39,297 11,062 Adjusted earnings per share attributable to shareholders of Orezone1 $ 0.04 0.01 0.08 0.03 Cash and Cash Flow Data Operating cash flow before changes in working capital $000's 27,023 15,331 67,009 36,671 Operating cash flow $000's 16,357 (51 ) 44,061 13,586 Free cash flow1 $000's (27,154 ) (16,951 ) (23,472 ) (14,938 ) Cash, end of period $000's 72,592 11,446 72,592 11,446 1 Cash costs, AISC, EBITDA, Adjusted EBITDA, Adjusted earnings, Adjusted earnings per share, and Free cash flow are non-IFRS measures. See 'Non-IFRS Measures' section below for additional information. SECOND QUARTER HIGHLIGHTS Strong Liquidity Maintained: Available liquidity stood at $103.9M at June 30, 2025 with $72.6M in cash and XOF 17.5 billion ($31.3M) undrawn on the Phase II term loan with Coris Bank International. The Company remains well-funded to execute on its 2025 and future growth plans. Robust EBITDA, Net Earnings, and Earnings Per Share: Reported Q2-2025 EBITDA of $40.3M, net earnings attributable to Orezone shareholders of $15.9M, and net earnings per share attributable to Orezone shareholders of $0.03 per share on a basic and diluted basis as earnings benefitted from the record rise in gold prices and unhedged gold sales in the current quarter. These earnings figures were 51%, 79%, and 50% higher, respectively, when compared against Q2-2024. Positive Operating Cash Flow Supporting Capital Investment: Reported Q2-2025 cash flow from operating activities of $27.0M after income tax payments of $14.9M but before changes in non-cash working capital. Non-cash working capital increased by $10.7M mainly from the build-up of VAT receivables and long-term ore stockpiles. Cash flow used in investing activities totalled $43.5M as progress and spending on the hard rock expansion and other growth projects accelerated. AISC Impacted by External Factors: AISC was elevated in Q2-2025 mainly due to higher royalties from a better realized gold price and new higher royalty rates (+$92/oz), low grid power availability due to a fire at a supply line substation and higher seasonal variability than forecasted (+$99/oz), and a stronger XOF currency impacting local costs (+$45/oz). Debt Reduction: Principal repayments totalling another XOF 3.0 billion ($5.2M) were made on the Company's senior debt in Q2-2025, bringing scheduled debt repayments to XOF 6.0 billion ($10.0M) in H1-2025. As of June 30, 2025, the principal on senior debt stood at XOF 36.5 billion ($65.3M). OPERATING HIGHLIGHTS Bomboré Mine, Burkina Faso (100% basis) Q2-2025 Q2-2024 H1-2025 H1-2024 Safety Lost-time injuries frequency rate Per 1M hours 0.55 0.00 0.31 0.00 Personnel-hours worked 000's hours 1,823 1,322 3,181 2,372 Mining Physicals Ore tonnes mined tonnes 2,059,136 1,966,547 4,173,679 4,369,080 Waste tonnes mined tonnes 3,948,902 3,451,757 7,967,084 6,574,856 Total tonnes mined tonnes 6,008,038 5,418,305 12,140,763 10,943,936 Strip ratio waste:ore 1.92 1.76 1.91 1.50 Processing Physicals Ore tonnes milled tonnes 1,565,022 1,428,396 3,076,325 2,784,015 Head grade milled Au g/t 0.62 0.64 0.65 0.71 Recovery rate % 87.8 86.8 87.8 88.0 Gold produced Au oz 27,548 25,524 56,236 55,663 Unit Cash Cost Mining cost per tonne $/tonne 3.27 3.29 3.04 3.38 Mining cost per ore tonne processed $/tonne 9.50 8.87 8.79 8.46 Processing cost $/tonne 9.65 9.19 8.74 9.21 Site general and admin ('G&A') cost $/tonne 4.36 3.96 4.08 3.87 Cash cost per ore tonne processed $/tonne 23.51 22.02 21.61 21.54 Cash Costs and AISC Details Mining cost (net of stockpile movements) $000's 14,869 12,672 27,045 23,539 Processing cost $000's 15,106 13,120 26,888 25,640 Site G&A cost $000's 6,824 5,654 12,542 10,788 Refining and transport cost $000's 113 136 279 253 Government royalty cost $000's 8,366 4,595 14,968 9,727 Gold inventory movements $000's 206 (1,625 ) (745 ) (209 ) Cash costs1 on a sales basis $000's 45,484 34,552 80,977 69,738 Sustaining capital $000's 4,284 3,281 7,483 7,299 Sustaining leases $000's 74 73 147 146 Corporate G&A $000's 1,880 2,319 4,062 4,388 All-In Sustaining Costs1 on a sales basis $000's 51,722 40,225 92,669 81,571 Gold sold Au oz 28,265 24,937 57,208 56,166 Cash costs per gold ounce sold1 $/oz 1,609 1,386 1,415 1,242 All-In Sustaining Costs per gold ounce sold1 $/oz 1,830 1,613 1,620 1,452 1 Non-IFRS measure. See 'Non-IFRS Measures' section below for additional details. BOMBORÉ PRODUCTION RESULTS Q2-2025 vs Q2-2024 Gold production in Q2-2025 was 27,548 oz, an increase of 8% from the 25,524 oz produced in Q2-2024. The higher gold production is attributable to a 10% increase in plant throughput and a 1% increase in recovery rates partially offset by a 3% decline in head grades. Plant throughput of 1.57M tonnes in Q2-2025 continues to operate ahead of nameplate by 20% and was 10% higher than Q2-2024 as plant operating hours in Q2-2024 were reduced by more frequent grid power interruptions and the longer length of time needed to transition power on and off of back-up diesel gensets during grid blackouts and restorations. Hourly plant throughput was successfully improved starting in July 2024 and maintained into 2025 by increasing the mill power draw and reducing residence time in the CIL circuit with only a minor loss in recovery. Transition time to switch between the grid and back-up gensets have also been lowered from improvements made to the site power infrastructure in Q1-2025. The better head grades in Q2-2024 were from the sequencing of higher-grade pits in earlier periods of the mine plan and the preferential stockpiling of lower-grade ore mined. BOMBORÉ OPERATING COSTS Q2-2025 vs Q2-2024 AISC per gold oz sold in Q2-2025 was $1,830, a 13% increase from $1,613 per oz sold in Q2-2024. The higher AISC is primarily attributable to: (a) greater per oz royalty costs ($296/oz vs $184/oz) from a 43% increase in the realized gold price and new higher royalty rates enacted into law in April 2025; (b) lower head grades; (c) a higher strip ratio; and (d) XOF currency appreciation against the USD (~5% higher) on costs set in the local currency. Power costs in both quarters suffered from high occurrences of power dips and blackouts to the national grid, resulting in more use of the back-up diesel gensets for power generation at the Bomboré mine. Grid supply is seasonally low in Q2, and similar to 2024, has significantly improved starting in Q3 with weekly grid utilization regularly exceeding 90%. For power consumed at the mine, the national grid supplied 50% in Q2-2025 and 34% in Q2-2024, leading to increased processing costs in these quarters from the use of higher-cost diesel for power generation. Cash cost per ore tonne processed in Q2-2025 was $23.51/tonne, an increase of 7% from $22.02/tonne in Q2-2024, driven by a stronger XOF currency impacting costs in all departments, a 9% increase in the strip ratio in mining, and higher unit consumption rates for power and lime in processing due to the changing composition of ore fed into the mill. BOMBORÉ HARD ROCK EXPANSION Hard Rock Expansion – Stage 1 Construction of the 2.5Mtpa stage 1 hard rock expansion remains on schedule and on budget, with first gold expected in Q4-2025. Progress and milestones achieved to the end of Q2-2025 include: Project completion reached 63% Engineering and drafting are complete Procurement is completed with all equipment and materials ordered. Focus is now on expediting critical path deliveries of electrical equipment and bulks to site. Final shipments of structural steel and tank platework, and other major mechanical equipment are either at site or in transit to site Concrete volume poured of 4,114 m3 (78% of estimated total) with foundations for SAG mill, water tanks, and pipe racks completed, and jaw crusher wing walls, conveyor footings, and other equipment foundations advancing All five CIL tanks are now erected to full height with hydrostatic testing underway Steel erection is progressing well Mill installation works commenced Operational readiness activities continue to progress with safety and training plans under preparation, and recruitment activities launched. Development of plant specific operating and maintenance procedures are underway All major site installation contracts (concrete, structural/mechanical/piping, electrical/instrumentation, and mill installation) were awarded to the same contractors that successfully delivered on the oxide construction. These contractors have now mobilized to site except for the electrical and instrumentation contractor whose team is scheduled to arrive in Q3-2025. As of June 30, 2025, the Company has incurred $57.0M in costs to-date against the project budget, of which $22.7M and $41.7M were incurred in Q2-2025 and H1-2025, respectively. Figure 1: Bomboré Processing Complex – Hard Rock Plant Layout (blue labels) Relative to Oxide Plant and Other Established Infrastructure (white labels)Figure 2: Stage 1 Hard Rock Expansion – Major Plant Component ConstructionHard Rock Expansion – Stage 2 On August 13, 2025, the Company's Board of Directors approved a final investment decision to proceed with stage 2 construction of the hard rock expansion. To the 2.5Mtpa stage 1 hard rock circuit, the stage 2 expansion to 5.5Mtpa comprises the addition of a ball mill, pebble crusher, thickener, oxygen plant, four additional CIL tanks, and a gold room upgrade. The latest capital cost estimate for the stage 2 hard rock expansion is $90M to $95M, with a construction timeline to first gold in Q4-2026 of 16 months. Once in commercial production, stage 2 is projected to increase overall gold production at Bomboré to 220,000-250,000 ounces per annum6. The Company intends to award engineering and procurement for the stage 2 expansion to Lycopodium. During Q2-2025, the Company contracted Lycopodium to perform front-end engineering and design, along with advancing procurement on long-lead equipment as part of stage 2 early works ahead of the approved final investment decision. As of June 30, 2025, the Company has incurred $0.4M in costs in Q2-2025 and for the project to-date. Figure 3: Schematic highlighting mill component additions for stage 2 hard rock expansion. Oxide plant and stage 1 hard rock circuit in grey.________________________6 Refer to footnote 1. CORPORATE AND SIGNIFICANT SUBSEQUENT EVENTS Corporate Bought Deal Equity Offering: In March 2025, the Company closed a bought deal offering including the over-allotment exercise by issuing 49,085,450 common shares at a price of C$0.82 per share for gross proceeds of C$40.3M ($28.0M) with net proceeds at C$37.6M ($26.1M) after commission and other transaction costs. Net proceeds from the offering will be used to fund construction costs for stage 2 of the hard rock expansion, exploration, working capital, and general corporate purposes. Private placement with Nioko Resources Corporation ('Nioko'): On April 2, 2025, the Company closed a non-brokered private placement with Nioko by issuing 10,719,659 common shares at a price of C$0.82 per share for gross proceeds of C$8.8M ($6.1M) in order to maintain its pro-rata share ownership in the Company. The net proceeds received from the share issuance was C$8.8M ($6.1M) after listing fees. Board of Director Changes: At the Company's AGM held on June 12, 2025, Mr. Julian Babarczy was elected as a new board member. Mr. Babarczy is an Australian resident with extensive knowledge of the Australian capital markets and deep relationships with many Australian institutional investment funds and brokerages. Mr. Babarczy will be an essential resource for the Company's local marketing efforts following the Company's recent listing on the ASX. Mr. Marco Locascio and Mr. Matthew Quinlan did not stand for re-election at the AGM. The Company is appreciative of the invaluable contributions and financial insights provided by Mr. Locascio and Mr. Quinlan during their respective tenures as directors. Subsequent Events Hard Rock Expansion – Stage 2 Construction Approval: The Company's Board of Directors approved a final investment decision to proceed with stage 2 construction of the hard rock expansion at its Bomboré mine. See Bomboré Hard Rock Expansion section for further details pertaining to the stage 2 hard rock expansion. ASX Public Offering and Listing: The Company was admitted to the official list of the ASX and commenced trading under the symbol 'ORE'. As part of the ASX listing, the Company completed an initial public offering of 65,789,474 CHESS Depository Interests ('CDIs') over fully paid common shares in the capital of the Company at an offer price of A$1.14 per CDI, raising gross proceeds of A$75.0 million. NON-IFRS MEASURES The Company has included certain terms or performance measures commonly used in the mining industry that is not defined under IFRS, including 'cash costs', 'AISC', 'EBITDA', 'adjusted EBITDA', 'adjusted earnings', 'adjusted earnings per share', and 'free cash flow'. Non-IFRS measures do not have any standardized meaning prescribed under IFRS, and therefore, they may not be comparable to similar measures presented by other companies. The Company uses such measures to provide additional information and they should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. For a complete description of how the Company calculates such measures and reconciliation of certain measures to IFRS terms, refer to 'Non-IFRS Measures' in the Management's Discussion and Analysis for the three months ended June 30, 2025 which is incorporated by reference herein. CONFERENCE CALL AND WEBCAST The condensed interim consolidated financial statements and Management's Discussion and Analysis are available at and on the Company's profile on SEDAR+ at Orezone will host a conference call and audio webcast to discuss its second quarter 2025 results on August 13, 2025: WebcastTiming: August 13, 2025, 2:00pm PT / 5:00pm ET / August 14, 2025, 7:00am AESTConference call webcast link: Conference CallToll-free in U.S. and Canada: 1-800-715-9871International callers: +646-307-1963 Event ID: 9884247 QUALIFIED PERSONS The scientific and technical information in this news release was reviewed and approved by Mr. Rob Henderson, P. Eng, Vice-President of Technical Services and Mr. Dale Tweed, P. Eng., Vice-President of Engineering, both of whom are Qualified Persons as defined under NI 43-101 Standards of Disclosure for Mineral Projects. ABOUT OREZONE GOLD CORPORATION Orezone Gold Corporation (TSX: ORE, ASX: ORE, OTCQX: ORZCF) is a West African gold producer engaged in mining, developing, and exploring its 90%-owned flagship Bomboré Gold Mine in Burkina Faso. Construction of the stage 1 hard rock expansion is well underway, with first gold expected in Q4-2025. Combined production from the oxide and stage 1 hard rock operations is forecasted to total between 170,000 and 185,000 ounces in 2026. The Company is also advancing the stage 2 hard rock expansion, which is forecasted to increase annual production to between 220,000 and 250,000 ounces. The technical report entitled Bomboré Phase II Expansion, Definitive Feasibility Study is available on SEDAR+ and the Company's website. Patrick DowneyPresident and Chief Executive Officer Kevin MacKenzieVice President, Corporate Development and Investor Relations Tel: 1 778 945 8977 info@ / For further information please contact Orezone at +1 (778) 945-8977 or visit the Company's website at The Toronto Stock Exchange neither approves nor disapproves the information contained in this news release. This announcement was authorised for release by the Company's Board of Directors. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' and 'forward-looking information', including statements and forecasts which include (without limitation) expectations regarding the financial position of the Company, production targets, the stage 1 and stage 2 hard rock expansions, the goal of defining a 7 to 10 million ounce resource base in the near future, future strategies, results and outlook of the Company and the opportunities available to the Company. Often, but not always, forward-looking information can be identified by the use of words such as plans', 'expects', 'is expected', 'is expecting', 'budget', 'outlook', 'scheduled', 'target', 'estimates', 'forecasts', 'intends', 'anticipates', or 'believes', or variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might', or 'will' be taken, occur or be achieved. Such information is based on assumptions and judgments of the Company regarding future events and results. Readers are cautioned that forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, targets, performance or achievements of the Company to be materially different from any future results, targets, performance or achievements expressed or implied by the forward-looking information. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the Directors and management of the Company. Past performance is not a guide to future performance. Key risk factors associated with an investment in the Company are detailed in the Company's audited annual consolidated financial statements, annual MD&A and Annual Information Form for the year ended December 31, 2024 as well as Section 4 of the Company's prospectus dated July 11, 2025, copies of which can be found on SEDAR+ and the Company's website. These and other factors could cause actual results to differ materially from those expressed in forward-looking statements. Forward-looking information and statements (including the Company's belief that it has a reasonable basis to expect it will be able to fund the hard rock expansion at the Bomboré Mine) are, further to the above, based on the reasonable assumptions, estimates, analysis and opinions of the Company made in light of its perception of trends, current conditions and expected developments, as well as other factors that the Company believes to be relevant and reasonable in the circumstances at the date such statements are made, but which may prove to be incorrect. Although the Company believes that the assumptions and expectations reflected in such forward-looking statements and information are reasonable, readers are cautioned that this is not exhaustive of all factors which may impact on the forward-looking information. The Company does not undertake to update any forward-looking information or statements, except in accordance with applicable securities laws. Due to the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. Figures accompanying this announcement are available at: in to access your portfolio
